Investor Insight Syntheia’s innovative conversational AI solution is transforming the face of customer engagement for the B2B market. Backed by a stable financial foundation, Syntheia is well-placed to execute its growth strategy, offering investors a compelling opportunity. Overview Syntheia (CSE:SYAI) has rapidly emerged as an innovative player in the expanding…
E-Power Resources Inc. (CSE: EPR) (‘E-Power’ or the ‘Company’) announces that it has closed a third and final tranche…
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas…
Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress…
Description During a fireside chat with analysts from Brookline Capital Markets, Radiopharm Theranostics’ (ASX:RAD) CEO Riccardo Canevari provided clinical…
Lightning Minerals (L1M or the Company) is delighted to announce the discovery of spodumene within a lithium bearing pegmatite…
Gunnison Copper (TSX:GCU,OTCQB:EXMGF) is shifting its development strategy for the Gunnison copper project in Arizona, US, laying out plans…
Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder. Click here…